Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: Interim results

Heinz Ludwig, Amos M. Cohen, Heinz Huber, David Nachbaur, Walter F. Jungi, Hansjörg Senn, Peter Günczler, Johannes Schüller, Sándor Eckhardt, Heinz L. Seewann, Franco Cavalli, Elke Fritz, Michael Micksche

Research output: Contribution to journalArticlepeer-review

Abstract

The present trial was designed to evaluate whether interferon (IFN) combined with standard induction chemotherapy and/or interferon remission maintenance treatment improve treatment results in patients with multiple myeloma. Up to now 89 patients have received IFN plus vincristine/melphalan/cyclophosphamide/prednisolone (VMCP) as induction therapy, and 86 conventional VMCP. The proportion of patients with progressive disease was significantly lower (P < 0.005) under IFN + VMCP as compared to the VMCP treatment group. Survival times were significantly longer (P < 0.02) after IFN + VMCP induction therapy than after VMCP alone. In the second phase of this investigation, 33 progression-free myeloma patients were assigned to receive IFN as maintenance therapy, and 41 patients served as untreated controls. Patients maintained with IFN showed a tendency towards increased progression-free survival. Haematological side effects were observed significantly more often in patients receiving IFN, with more severe haematological toxicity in patients on the combined IFN + VMCP regimen and an increased number of patients with mild haematological toxicity in the group maintained with IFN. Other side effects, such as fever and fatigue, remained within tolerable limits. In conclusion, the preliminary results of this current clinical trial indicate significant advantages of combined IFN + VMCP induction treatment in terms of reduced disease progression and prolonged survival and possible benefits of IFN maintenance therapy in patients with multiple myeloma.

Original languageEnglish
Pages (from-to)S40-S45
JournalEuropean Journal of Cancer and Clinical Oncology
Volume27
Issue numberSUPPL. 4
DOIs
StatePublished - Dec 1991
Externally publishedYes

Fingerprint

Dive into the research topics of 'Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: Interim results'. Together they form a unique fingerprint.

Cite this